Heart failure & cardiomyopathies
Sacubitril/Valsartan and Cardiovascular Biomarkers Among Patients with Recent COVID-19 Infection: The PARACOR-19 Randomized Clinical Trial
Authors' conclusion
In this pilot RCT of patients who recovered from acute COVID-19, sacubitril/valsartan did not lower hs-cTnT or sST2 compared with placebo.
Study context
- Population
- Patients with CV risk factors and COVID-19 infection 4–16 weeks before enrolment
- Participants
- 42 patients
- Comparison
- Sacubitril/valsartan vs placebo
- Sacubitril/valsartann = 20
- Placebon = 22reference
- Primary endpoint
- Co-primary: change from baseline in high-sensitivity cardiac troponin T (hs-cTnT) and sST2
- Follow-up
- 12 weeks
Methodological detailssingle-centre, double-blind, placebo-controlled, pilot
- Single-centre
- Double-blind
- Placebo-controlled
- Pilot
Primary result
As reported in the abstract
Change in hs-cTnT and sST2
- No significant effect of sacubitril/valsartan vs placebo on change in hs-TnT and soluble ST2 (sST2)
- all p ≥ 0.29
Further findings
| Outcome | Sacubitril/valsartan | Placebo |
|---|---|---|
| Death and hospitalisation | ||
| Deaths | 0 | 0 |
| Hospitalised | 1 | 1 |
NT-proBNP (exploratory) · 12 weeks
- Greater reduction with sacubitril/valsartan
- 46%
- Exploratory analysis
CITP (exploratory) · 12 weeks
- Greater reduction with sacubitril/valsartan
- 51%
- Exploratory analysis
Safety
Events
| Outcome | Sacubitril/valsartan | Placebo |
|---|---|---|
| Permanent drug discontinuation | 4 | 3 |
Original publication
Sacubitril/Valsartan and Cardiovascular Biomarkers Among Patients with Recent COVID-19 Infection: The PARACOR-19 Randomized Clinical Trial. Eur J Heart Fail. Published 11 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →